
THIS SUPPLEMENTAL CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt as to any aspect of this supplemental circular or as to the action to be taken, you should consult a stockbroker or other registered dealer in securities, a bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all your shares in Biosino Bio-Technology and Science Incorporation, you should at once hand this supplemental circular, together with the enclosed revised form of proxy, to the purchaser or transferee or to the bank, stockbroker or other agent through whom the sale was effected for transmission to the purchaser or transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this supplemental circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this supplemental circular.



中生北控生物科技股份有限公司
BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION
(a joint stock limited company incorporated in the People's Republic of China with limited liability)
(Stock Code: 8247)

SUPPLEMENTAL CIRCULAR TO THE CIRCULAR DATED 4 MAY 2023
(1) PROPOSED APPOINTMENT AND RE-APPOINTMENT OF DIRECTORS;
(2) PROPOSED APPOINTMENT OF AND RE-APPOINTMENT OF SUPERVISORS;
AND
(3) SUPPLEMENTAL NOTICE OF THE ANNUAL GENERAL MEETING

This supplemental circular should be read in conjunction with the circular of the Company dated 4 May 2023 (the “**Original Circular**”).

A notice (the “**Original Notice**”) convening the Annual General Meeting (“**AGM**”) of the Company to be held at No. 27 Chaoqian Road, Science and Technology Industrial Park, Changping District, Beijing, the PRC on Thursday, 25 May 2023 at 10:00 a.m. has been issued by the Company on 6 April 2023. Due to the addition of the new resolutions, a supplemental notice of the AGM (the “**Supplemental Notice**”) has been set out on pages 17 to 19 of this supplemental circular. The Supplemental Notice should be read in conjunction with the Original Notice.

A revised form of proxy for use at the AGM is enclosed herewith and is also published on the websites of Hong Kong Exchanges and Clearing Limited (www.hkexnews.hk) and the Company (www.zhongsheng.com.cn). Whether or not you intend to attend the AGM, you are requested to complete and return the revised form of proxy in accordance with the instructions printed thereon not less than 24 hours before the time fixed for holding the AGM or any adjournment thereof (as the case may be). Completion and return of the revised form of proxy will not preclude you from attending the AGM and voting in person if you so wish.

This supplemental circular will remain on the website of Hong Kong Exchanges and Clearing Limited on the “Latest Listed Company Information” page for at least 7 days from the date of its posting.

10 May 2023

CHARACTERISTICS OF GEM

GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration.

Given that the companies listed on GEM are generally small and mid-sized companies, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board of the Stock Exchange and no assurance is given that there will be a liquid market in the securities traded on GEM.

CONTENTS

	<i>Page</i>
Letter from the Board	
Introduction	1
Proposed Appointment and Re-appointment of Directors	2
Proposed Appointment and Re-appointment of Supervisors	4
AGM and Proxy Arrangement	4
Recommendation	5
Appendix I – The Biographies of Directors Proposed to be Appointed and Re-appointed	6
Appendix II – The Biographies of Supervisors Proposed to be Appointed and Re-appointed	15
Supplemental Notice of the Annual General Meeting	17

LETTER FROM THE BOARD



中生北控生物科技股份有限公司
BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION
(a joint stock limited company incorporated in the People's Republic of China with limited liability)
(Stock Code: 8247)

Chairman and executive Director

Mr. Wu Lebin (吳樂斌先生)

Vice-chairman and executive Director

Mr. Lin Yanglin (林楊林先生)

Vice-chairman and non-executive Director

Dr. Sun Zhe (孫哲博士)

Non-executive Director

Ms. Cheng Yali (程亞利女士)

Independent non-executive Directors

Dr. Zheng Yongtang (鄭永唐博士)

Mr. Lu Qi (陸琪先生)

Prof. Shen Jiangang (沈劍剛教授)

*Registered office and principal place
of business in the PRC:*

No. 27 Chaoqian Road
Science and Technology Industrial Park
Changping District
Beijing, PRC

*Principal place of business
in Hong Kong:*

66/F., Central Plaza
18 Harbour Road
Wanchai
Hong Kong

10 May 2023

To the Shareholders

Dear Sir/Madam,

SUPPLEMENTAL CIRCULAR TO THE CIRCULAR DATED 4 MAY 2023
(1) PROPOSED APPOINTMENT AND RE-APPOINTMENT OF DIRECTORS;
(2) PROPOSED APPOINTMENT AND RE-APPOINTMENT OF SUPERVISORS;
AND
(3) SUPPLEMENTAL NOTICE OF THE ANNUAL GENERAL MEETING

INTRODUCTION

References are made to the Original Circular dated 4 May 2023 and the Original Notice of the AGM dated 6 April 2023, which set out the time and venue of the AGM and contain the resolutions to be proposed at the AGM for Shareholders' consideration and approval. This supplemental circular should be read in conjunction with the Original Circular. Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Original Circular.

LETTER FROM THE BOARD

The main purpose of this supplemental circular is to provide you with information regarding the proposed appointment and re-appointment of Directors and Supervisors (as defined below) and the additional ordinary resolutions relating thereto to be proposed at the AGM.

PROPOSED APPOINTMENT AND RE-APPOINTMENT OF DIRECTORS

According to Article 96 of the Articles of Association and the respective Shareholders' resolutions approving the appointments of the Directors, all Directors' appointments will expire after three years. Thus, save and except Mr. Lin Yanglin, Ms. Cheng Yali and Dr. Zheng Yongtang, who will not offer themselves for re-appointment as they would like to devote more time on their other commitments, the remaining Directors namely, Mr. Wu Lebin, Dr. Sun Zhe, Mr. Lu Qi and Prof. Shen Jiangang, will offer themselves for re-appointment at the AGM.

Ordinary resolutions will be proposed at the AGM to re-appoint Mr. Wu Lebin as an executive Director, to re-appoint Dr. Sun Zhe as a non-executive Director, and to re-appoint each of Mr. Lu Qi and Prof. Shen Jiangang as an independent non-executive Director of the eighth session of the Board.

It is proposed that Mr. Chen Peng will be appointed as an executive Director, Mr. Chen Zhengyong, Mr. Li Zhonghua and Dr. Gao Guangxia as non-executive Directors and Prof. Shen Zuojun as an independent non-executive Director of the eighth session of the Board and ordinary resolutions will be proposed at the AGM to such effect. Biographical details of each of the proposed Directors to be appointed and re-appointed are set out in Appendix I to this supplemental circular.

LETTER FROM THE BOARD

The nominees for the eighth session of the Board include three independent non-executive Directors which constitute one-third of the Board, fulfilling the relevant requirements under the GEM Listing Rules. Apart from the two nominees proposed for re-appointment as independent non-executive Directors, the Company also identified suitable new independent non-executive Director candidates through multiple channels. The criteria for such candidates include but are not limited to candidates' character and integrity, professional qualifications, skills, knowledge and experience, independence, diversity on the Board, willingness to devote adequate time to discharge duties as a Board member and such other criteria that are appropriate to the business of the Company. In considering the proposed re-appointment and appointment of independent non-executive Directors, the nomination committee of the Company (the “**Nomination Committee**”) and the Board have taken into account the following factors:

1. The nominees for independent non-executive Directors have extensive and solid experience in different sectors including finance, law, banking, management, economics, research experience in Chinese medicine, clinical laboratory, etc. Their education, background, experience and practical experience enable them to provide valuable and diversified opinions. During their respective tenure, Mr. Lu Qi and Prof. Shen Jiangan have proactively and diligently carried out their duties as independent non-executive Directors and have provided valuable independent advice on the affairs of the Company from time to time with their professional knowledge and comprehensive experience.
2. The Company has conducted an assessment on their independence and is of the view that each of them complies with the independence requirement pursuant to Rule 5.09 of the GEM Listing Rules and that they are considered as independent.
3. None of the nominees for independent non-executive Directors holds position as a director in seven or more listed companies. They are able to devote sufficient time and attention to the Company.

Accordingly, the Nomination Committee and the Board are of the view that the re-appointment and appointment of the three nominees to be independent non-executive Directors can enhance the level of management of the Company by virtue of their professional knowledge and extensive experience, while promoting the independence and objectiveness in decision-making of the Board and the comprehensive and impartial supervision of the management of the Company, which is in the interests of the Company and the Shareholders as a whole.

LETTER FROM THE BOARD

PROPOSED APPOINTMENT AND RE-APPOINTMENT OF SUPERVISORS

According to Article 118 of the Articles of Association and the respective Shareholders' resolutions approving their appointments, each appointment of the supervisors of the Company (the "Supervisor(s)") will expire after three years. Mr. Zhou Jie will not offer himself for re-appointment as he would like to devote more time on his other commitments. Dr. Shen Sheng will offer himself for re-appointment and an ordinary resolution will be proposed at the AGM to re-appoint him as a Supervisor.

It is proposed that Mr. Li Jifeng will be appointed as a Supervisor of the eighth session of the supervisory committee of the Company and an ordinary resolution will be proposed at the AGM to such effect. Biographical details of each of the proposed Supervisors to be appointed and re-appointed are set out in Appendix II to this supplemental circular.

AGM AND PROXY ARRANGEMENT

Due to the addition of the new resolutions, the Supplemental Notice has been set out on pages 17 to 19 of this supplemental circular. At the AGM, resolutions will be proposed to approve, inter alia, the proposed appointment and re-appointment of Directors, the proposed appointment and re-appointment of Supervisors, the Proposed Amendments to the Existing Articles and the granting of the General Mandate to issue new Shares.

Pursuant to Rule 17.47(4) of the GEM Listing Rules, any vote of Shareholders at a general meeting must be taken by poll. Accordingly, all resolutions will be put to vote by way of poll at the AGM. An announcement on the poll vote results will be made by the Company after the AGM in the manner prescribed under Rule 17.47(5) of the GEM Listing Rules.

A revised form of proxy for use at the AGM is enclosed with the Supplemental Notice and such revised form of proxy is also published on the website of Hong Kong Exchanges and Clearing Limited (hkexnews.hk) and the Company's website (www.zhongsheng.com.cn). Whether or not you intend to attend the AGM, you are requested to complete and return the revised form of proxy in accordance with the instructions printed thereon not less than 24 hours before the time fixed for holding the AGM or any adjournment thereof (as the case may be). Completion and return of the revised form of proxy will not preclude you from attending the AGM and voting in person if you so wish.

LETTER FROM THE BOARD

If you wish to appoint a proxy to attend and vote at the AGM on your behalf and if you have not yet returned the first proxy form dated 6 April 2023 (the “**First Proxy Form**”), you should complete, sign and return the revised form of proxy to Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong no later than 48 hours before the time appointed for holding the AGM or any of its adjournments (as the case may be) (the “**Closing Time**”). In this case, the First Proxy Form should not be submitted.

If you wish to appoint a proxy to attend and vote at the AGM on your behalf, and have already duly completed and submitted the First Proxy Form, you should note that: (a) if the revised form of proxy is not submitted, the First Proxy Form correctly completed and duly lodged will be treated as a valid proxy form submitted by you. The proxy so appointed shall be required to vote in such manner as he/she may be directed under the First Proxy Form and, in respect of the resolutions set out in the Supplemental Notice, the proxy will be entitled to vote at his/her discretion or to abstain from voting on such resolutions; (b) if the revised form of proxy is duly completed and submitted by the Closing Time, such revised form of proxy will supersede the First Proxy Form submitted by you. The revised form of proxy will be treated as a valid proxy form submitted by you; and (c) if the revised form of proxy is submitted after the Closing Time, such revised form of proxy will be invalid and the validity of the First Proxy Form correctly completed and duly submitted by you will not be affected. The proxy appointed by you under the First Proxy Form (if duly completed) will be entitled to vote in the manner as mentioned in (a), as if the revised form of proxy is not lodged.

RECOMMENDATION

The Directors believe that all resolutions proposed for consideration and approval by the Shareholders at the AGM are in the best interests of the Company and the Shareholders as a whole. Accordingly, the Directors recommend that all the Shareholders should vote in favour of the resolutions to be proposed at the AGM as set out in the Original Notice and the Supplemental Notice.

Yours faithfully,

For and on behalf of the Board

Biosino Bio-Technology and Science Incorporation

Tung Woon Cheung, Eric

Company Secretary

The following are the particulars of the Directors proposed to be appointed and re-appointed at the AGM:

EXECUTIVE DIRECTORS

Mr. WU Lebin (吳樂斌先生) (“**Mr. Wu**”), aged 61, is the chairman of the Board, an executive Director and the legal representative of the Company. Mr. Wu is responsible for the approval and supervision of the overall strategies and policies of the Group, approval of annual budgets and business plans, evaluation of the Group’s performance and overseeing the management. Mr. Wu graduated from Jiangxi Medical College with a bachelor degree in medicine in 1983 and from the Graduate University of Chinese Academy of Sciences with a master degree in science in 1988. He also completed an EMBA study program jointly offered by the University of Wisconsin of the United States and the Graduate University of Chinese Academy of Sciences (the “**CAS**”) in 2002. Prior to joining the Group, Mr. Wu served as the director and the deputy director in the CAS and the deputy director in the Institute of Biophysics (the “**IBP**”) of the CAS respectively. He possesses over 20 years of experience in research management, science development, administration and corporate management. Mr. Wu joined the Company in 2001. He served as the president of the Company between 2003 and 2014, and again between 2019 and 2020, and has been acting as the Chairman since 2006. Since June 2014, he served as the secretary of the Party committee of CAS and as the chairman of the board in CAS Holdings from June 2014 to October 2019.

As at the Latest Practicable Date, Mr. Wu held 3,500,878 Domestic Shares, representing approximately 4.35% of the total number of Domestic Shares and approximately 2.42% of the total issued share capital of the Company.

The Company proposes to re-appoint Mr. Wu as an executive Director to hold office for a term of three years until the expiration of the term of the current session of the Board. Subject to the Shareholders’ approval at the AGM, his emoluments will be determined by the Board with reference to his responsibilities and performance of duties to the Company.

As at the Latest Practicable Date, Mr. Wu did not hold any directorship in other public listed company in Hong Kong or overseas in the last three years nor any other position with the Company or other members of the Group. In addition, Mr. Wu does not have any relationship with the other Directors, Supervisors, senior management or substantial or controlling Shareholders. There is no other information which is discloseable, nor is/was Mr. Wu involved in any of the matters required to be disclosed pursuant to Rule 17.50(2)(h) to 17.50(2)(v) of the GEM Listing Rules. There is no other matter in relation to the proposed re-appointment of Mr. Wu as an executive Director that needs to be brought to the attention of the Shareholders.

Mr. CHEN Peng (陳鵬先生), aged 49, was appointed as the president of the Company on 7 December 2021. He graduated from Anhui University of Chinese Medicine (安徽中醫學院) with a bachelor's degree in Integrated Chinese and Western Medicine (中西醫結合臨床專業) in 1998. He served as the technical director of Shanghai Fosun High-tech (Group) Co., Ltd.* (上海復星高科技(集團)公司), a director of Anhui Guoke Kangyi Medical Technology Co., Ltd.* (安徽國科康儀醫療科技有限公司) and Hefei Guoke Kangyi Medical Laboratory Co., Ltd.* (合肥國科康儀醫學檢驗實驗室有限公司), the chairman and president of Hefei Anhui Meikang Hospital Investment Management Co., Ltd. (合肥安徽美康醫院投資管理股份有限公司), the general manager of Guoke Health Hospital Industry (Hefei) Co., Ltd.* (國科健康醫院產業(合肥)有限公司), the chairman of Guoke Health Information Technology (Anhui) Co., Ltd. (國科健康信息科技(安徽)有限公司) and the chairman of Step Stone (Suzhou) Biotechnology Co., Ltd. (踏石(蘇州)生物技術有限公司). He joined the Company in December 2021.

Subject to the Shareholders' approval of Mr. Chen Peng's appointment as an executive Director, the Company will enter into a service agreement with Mr. Chen Peng and his term of service with the Company will end at the expiration of the term of the current session of the Board. His remuneration will be determined by the Board and the Remuneration Committee with reference to his duties and responsibilities, the performance of the Group and the prevailing market conditions.

Save as disclosed above, Mr. Chen Peng does not hold any directorship in any public companies where the securities of which are listed on any securities markets in Hong Kong or overseas in the last three years or any other positions with the Company and other members of the Group or have other major appointments and professional qualifications.

As at the Latest Practicable Date, Jingning Guoke Kangyi Enterprise Management Center LLP* (景寧國科康儀企業管理中心(有限合夥)) (“Jingning”) owned 11,330,334 Domestic Shares and Mr. Chen Peng owns 99.5% of equity interests in Jingning. Accordingly, he is deemed to be interested in the 11,330,334 Domestic Shares owned by Jingning. Other than disclosed above, he does not have, and is not deemed to have any interests or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations which are required to be disclosed pursuant to Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

As at the Latest Practicable Date, other than being the father of Ms. Chen Chen (陳晨), a substantial Shareholder, Mr. Chen Peng does not have any relationship with the Directors, senior management, substantial or controlling shareholders of the Company as defined in the GEM Listing Rules.

There are no other matters relating to the appointment of Mr. Chen Peng that need to be brought to the attention of the shareholders of the Company and there is no other information that should be disclosed pursuant to Rule 17.50(2)(h) to 17.50(2)(v) of the GEM Listing Rules.

NON-EXECUTIVE DIRECTORS

Dr. SUN Zhe (孫哲博士) (“Dr. Sun”), aged 48, is a non-executive Director and the vice chairman of the Company. She obtained a doctoral degree of biochemistry from the University of Heidelberg, Germany. She is currently a director and an associate researcher of the Science and Technology Cooperation and Achievement Transformation Division (科技合作與成果轉化處) in IBP of the CAS. She has extensive experience in conducting biochemical and biological researches. Dr. Sun joined the Company in September 2018.

The Company proposes to re-appoint Dr. Sun as a non-executive Director to hold office for a term of three years until the expiration of the term of the current session of the Board. Subject to the Shareholders’ approval at the AGM, her emoluments will be determined by the Board with reference to her responsibilities and performance of duties to the Company.

As at the Latest Practicable Date, Dr. Sun did not hold any directorship in other public listed company in Hong Kong or overseas in the last three years nor any other position with the Company or other members of the Group. In addition, She does not have any relationship with the other Directors, Supervisors, senior management or substantial or controlling Shareholders, nor has any interests in the Shares within the meaning of Part XV of the SFO. There is no other information which is discloseable, nor is/was she involved in any of the matters required to be disclosed pursuant to Rule 17.50(2)(h) to 17.50(2)(v) of the GEM Listing Rules. There is no other matter in relation to the proposed re-appointment of Dr. Sun as a non-executive Director that needs to be brought to the attention of the Shareholders.

Mr. CHEN Zhengyong (陳正永先生), aged 60, has over 40 years of experience in the PRC medical testing and in vitro diagnostic industry. From 1983 to 1993, he was employed at Chengdu Tenth Hospital* (成都市第十醫院) where he was responsible for diagnostic testing. Since 1994, he has been engaged in the business of precision medicine and in vitro diagnostic. He has served as the chairman of the board of a number of companies including Sichuan Zhong Sheng Medical Devices Co., Ltd.* (四川中生醫療器械有限責任公司) since 2012, Sichuan Century Tongchang Health Management Co., Ltd.* (四川世紀同昌健康管理有限責任公司) since 2015 and Chengdu Tongchang Medical Laboratory Co., Ltd.* (成都同昌醫學檢驗所有限公司) since 2017.

Mr. Chen Zhengyong obtained his diploma from Chongqing Medical and Pharmaceutical College (重慶醫藥高等專科學校) in clinical laboratory (檢驗專業) in 1983. He studied Chinese language and literature (漢語言文學專業) at Sichuan Broadcast Television University* (四川省廣播電視大學) (currently known as Sichuan Open University (四川開放大學)) from 1985 to 1988, studied Master of Business Administration at Sichuan University of Finance and Economics (四川財經大學) from 2014 to 2016 and studied Master of Business Administration at Peking University (北京大學) from 2018 to 2020.

Subject to the Shareholders' approval of Mr. Chen Zhengyong's appointment as a non-executive Director, the Company will enter into a service agreement with him and his term of service with the Company will end at the expiration of the term of the current session of the Board. His remuneration will be determined by the Board and the remuneration committee of the Company (the "**Remuneration Committee**") with reference to his duties and responsibilities, the performance of the Group and the prevailing market conditions.

Save as disclosed above, Mr. Chen Zhengyong does not hold any directorship in any public companies where the securities of which are listed on any securities markets in Hong Kong or overseas in the last three years or any other positions with the Company and other members of the Group or have other major appointments and professional qualifications.

As at the Latest Practicable Date, Sichuan Zhongsheng Medical Instrument Co., Ltd. ("**Sichuan Zhongsheng**") owned 10,000,000 Domestic Shares. As the equity interests of Sichuan Zhongsheng were owned as to 75.35% by Mr. Chen Zhengyong, he is deemed to be interested in the Domestic Shares owned by Sichuan Zhongsheng pursuant to the SFO. Accordingly, he is deemed to be interested in the 10,000,000 Domestic Shares owned by Jingning. Other than disclosed above, he does not have, and is not deemed to have any interests or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations which are required to be disclosed pursuant to Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

As at the Latest Practicable Date, other than being the father of Ms. Chen Zhaoyang (陳昭陽), a substantial Shareholder, Mr. Chen Zhengyong did not have any relationship with the Directors, senior management, substantial or controlling shareholders of the Company as defined in the GEM Listing Rules. There are no other matters relating to the appointment of Mr. Chen Zhengyong that need to be brought to the attention of the shareholders of the Company and there is no other information that should be disclosed pursuant to Rule 17.50(2)(h) to 17.50(2)(v) of the GEM Listing Rules.

Mr. LI Zhonghua (李忠華先生) (“Mr. Li”), aged 60, is proposed to be appointed as a non-executive Director. Mr. Li has experience working as a supervisor teach in medical diagnostic profession, a secretary and deputy secretary of the Youth League Committee (團委書記及副書記), a clinical laboratory doctor at the hospital. Currently, Mr. Li serves as the deputy director of the Pharmaceutical Professional Committee* of the Yunnan Provincial Party Committee of the Peasants and Workers Democratic Party* (農工民主黨雲南省委藥物專業委員會副主任). From 1993 to December 1997, Mr. Li worked at Shanghai Kehua Biotechnology Co., Ltd.* (上海科華生物科技股份有限公司工作). In 1998, Mr. Li commenced his own business and was a senior management personnel that inspects medical equipment products in Yunnan Province. Mr. Li founded Kunming Huasheng Technology Co., Ltd.* (昆明華聖科技有限公司) and Yunnan Guoke Kangyi Biotechnology Co., Ltd.* (雲南國科康儀生物科技股份有限公司). Mr. Li was a graduate student at Kunming Medical University (昆明醫科大學) (previously known as Kunming Medical College (昆明醫學院)) and obtained his EMBA degree from Peking University HSBC Business School.

Subject to the Shareholders’ approval of Mr. Li’s appointment as a non-executive Director, the Company will enter into a service agreement with Mr. Li and his term of service with the Company will end at the expiration of the term of the current session of the Board. His remuneration will be determined by the Board and the Remuneration Committee with reference to his duties and responsibilities, the performance of the Group and the prevailing market conditions.

Save as disclosed above, Mr. Li does not hold any directorship in any public companies where the securities of which are listed on any securities markets in Hong Kong or overseas in the last three years or any other positions with the Company and other members of the Group or have other major appointments and professional qualifications. Mr. Li does not have, and is not deemed to have any interests or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations which are required to be disclosed pursuant to Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

As at the Latest Practicable Date, other than being the father of Mr. Li Yangyixiong, a substantial Shareholder, Mr. Li did not have any relationship with the Directors, senior management, substantial or controlling shareholders of the Company as defined in the GEM Listing Rules.

There are no other matters relating to the appointment of Mr. Li that need to be brought to the attention of the shareholders of the Company and there is no other information that should be disclosed pursuant to Rule 17.50(2)(h) to 17.50(2)(v) of the GEM Listing Rules.

Dr. GAO Guangxia (高光俠博士) (“Dr. Gao”), aged 58, joined the Company in January 2007 and acted as a non-executive director and the vice chairman of the Company between January 2007 and October 2014. He is currently as a research scientist at the IBP of Chinese Academy of Sciences, a director of the main laboratory of infection and immunity at Chinese Academy of Sciences, the legal representative of Beijing Pusai Funds Management Co., Ltd. He was previously the deputy director of the IBP of Chinese Academy of Sciences.

Dr. Gao obtained his bachelor’s degree with a major in biochemistry from Peking University in 1988 and his doctorate degree from the department of biochemistry of Columbia University, the United States in 1995. He was a postdoctoral fellow at the Howard Hughes Medical Institute of Columbia University, the United States from 1995 to 1999 and was appointed as an associate research scientist in the Department of Biochemistry of Columbia University, the United States from 1999 to 2001. Since 2001, he has participated as a researcher in the One Hundred Talent Project (百人計劃) of Chinese Academy of Sciences. He received sponsorship from the National Outstanding Youth Fund (國家傑出青年基金) in 2002.

Subject to the Shareholders’ approval of Dr. Gao’s appointment as a non-executive Director, the Company will enter into a service agreement with him and his term of service with the Company will end at the expiration of the term of the current session of the Board. His remuneration will be determined by the Board and the Remuneration Committee with reference to his duties and responsibilities, the performance of the Group and the prevailing market conditions.

As at the Latest Practicable Date, Dr. Gao did not hold any directorship in other public listed company in Hong Kong or overseas in the last three years nor any other position with the Company or other members of the Group. In addition, he does not have any relationship with the other Directors, Supervisors, senior management or substantial or controlling Shareholders, nor has any interests in the Shares within the meaning of Part XV of the SFO.

There is no other information which is discloseable, nor is/was Dr. Gao involved in any of the matters required to be disclosed pursuant to Rule 17.50(2)(h) to 17.50(2)(v) of the GEM Listing Rules. There is no other matter in relation to the proposed re-appointment of Dr. Gao as a non-executive Director that needs to be brought to the attention of the Shareholders.

INDEPENDENT NON-EXECUTIVE DIRECTORS

Mr. LU Qi (陸琪先生) (“**Mr. Lu**”), aged 42, obtained his Bachelor of Law degree from Central University of Finance and Economics (中央財經大學) from September 1999 to July 2003, and a Master of Civil and Commercial Law degree from Central University of Finance and Economics (中央財經大學) in June 2009. He is currently a PhD student in Finance at Northeastern University (東北大學). From August 2003 to October 2011, he worked at the Zhejiang Branch of Industrial and Commercial Bank of China (中國工商銀行浙江省分行) and Zhejiang Branch of China Development Bank (國家開發銀行浙江省分行). Since September 2011, he has served as a secretary to the president at China Economic System Reform Research Association (中國經濟體制改革研究會). He has acted as deputy director at the Internet and New Economy Committee (互聯網和新經濟專業委員會) since July 2019. Mr. Lu joined the Company in May 2021.

The Company proposes to re-appoint Mr. Lu as an independent non-executive Director to hold office for a term of three years until the expiration of the term of the current session of the Board. Subject to the Shareholders’ approval at the AGM, his emoluments will be determined by the Board with reference to his responsibilities and performance of duties to the Company.

As at the Latest Practicable Date, Mr. Lu did not hold any directorship in other publicly listed company in Hong Kong or overseas in the last three years or any other positions with the Company and other members of the Group or have other major appointments and professional qualifications. Mr. Lu does not have, and is not deemed to have any interests or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations which are required to be disclosed pursuant to Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Mr. Lu does not have any relationship with other Directors, senior management, substantial or controlling Shareholders as defined in the GEM Listing Rules.

Save as disclosed above, Mr. Lu has met the independence criteria set out in Rule 5.09 of the GEM Listing Rules and there is nothing in respect of the proposed appointment of Mr. Lu that needs to be brought to the attention of the Shareholders nor is there anything that needs to be disclosed pursuant to Rule 17.50(2)(h) to (v) of the GEM Listing Rules.

Prof. SHEN Jiangan (沈劍剛教授), aged 59, was appointed as an independent non-executive Director with effect from 23 February 2023. He acted as a professor and chairman of the Departmental Research Postgraduate Committee at School of Chinese Medicine of The University of Hong Kong since February 2022. From July 2014 to February 2020, he acted as a professor and associate director (research) of School of Chinese Medicine at The University of Hong Kong. From January 2013 to July 2014, he acted as a professor and assistant director (research) of School of Chinese Medicine at The University of Hong Kong. From November 2005 to January 2007, he acted as an assistant professor at School of Chinese Medicine of The Chinese University of Hong Kong. From August 2004 to December 2005, he served as an assistant professor (research) at College of Pharmacy, Health Science Center, University of New Mexico in the United States of America (the “**United States**”). From September 2001 to September 2004, he served as a research assistant professor at the Department of Medicine of The University of Hong Kong. From August 1999 to September 2001, he was employed as a research scientist at National EPR Center, Department of Radiology at Dartmouth Medical School in the United States. From July 1995 to July 1998, he acted as an associate professor and associate director at Institute of Chinese Medicine, Nan-Fang Hospital, First Military Medical University (currently known as Southern Medical University) in China. From July 1990 to July 1995, he was a lecturer at Institute of Chinese Medicine, Nan-Fang Hospital, First Military Medical University in China.

The Company proposes to re-appoint Prof. Shen Jiangan as an independent non-executive Director to hold office for a term of three years until the expiration of the term of the current session of the Board. Subject to the Shareholders’ approval at the AGM, his emoluments will be determined by the Board with reference to his responsibilities and performance of duties to the Company.

As at the Latest Practicable Date, Prof. Shen Jiangan did not hold any directorship in other publicly listed company in Hong Kong or overseas in the last three years or any other positions with the Company and other members of the Group or have other major appointments and professional qualifications. He does not have, and is not deemed to have any interests or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations which are required to be disclosed pursuant to Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). He does not have any relationship with other Directors, senior management, substantial or controlling Shareholders as defined in the GEM Listing Rules.

Save as disclosed above, Prof. Shen Jiangan has met the independence criteria set out in Rule 5.09 of the GEM Listing Rules and there is nothing in respect of the proposed appointment of him that needs to be brought to the attention of the Shareholders nor is there anything that needs to be disclosed pursuant to Rule 17.50(2)(h) to (v) of the GEM Listing Rules.

Prof. SHEN Zuojun (沈佐君教授), aged 60, is proposed to be appointed as an independent non-executive Director. He currently holds a number of positions including being an associate professor, a supervisor to doctorate degree students and a supervisor diagnostician (一級主任檢驗師) at the First Affiliated Hospital of the University of Science and Technology of China (中國科學技術大學附屬第一醫院) (also known as Anhui Provincial Hospital (安徽省立醫院)). In 1998, he obtained his doctorate degree in medicine (醫學博士學位) from China Union Medical College (中國協和醫科大學). From 1998 to 2000, he was a post-doctoral fellow (博士後) at Harvard Medical School in the United States.

In 2017, Prof. Shen Zuojun was awarded as one of the 8th “National Health and Family Planning Outstanding Contribution for the Youth and Middle Aged Experts (國家衛生計生突出貢獻中青年專家)” and in 2018, he obtained special allowance from the State Council. He is currently a national member of the Clinical Laboratory Professional Committee (臨床檢驗專業委員會) of the Chinese Hospital Management Society* (中華醫院管理學會), a national member of the Health Professional Qualification Examination Expert Committee (衛生專業技術資格考試專家委員會), a member of the American Association for Clinical Chemistry (美國臨床化學會), and an editorial member of Chinese Journal of Laboratory Medicine* (中華檢驗醫學雜誌), Journal of Clinical Blood Transfusion and Laboratory* (臨床輸血與檢驗雜誌), Journal of Clinical Laboratory* (臨床檢驗雜誌).

Prof. Shen Zuojun will enter into a service agreement with the Company upon his appointment as an independent non-executive Director is approved by the Shareholders at the AGM. His term of service with the Company will take effect from the date of approval by the Shareholders at the AGM until the expiration of the term of the current session of the Board. His remuneration will be determined by the Board and the Remuneration Committee with reference to his duties and responsibilities, the performance of the Group and the prevailing market conditions.

Save as disclosed above, Prof. Shen Zuojun does not hold any directorship in any public companies where the securities of which are listed on any securities markets in Hong Kong or overseas in the last three years or any other positions with the Company and other members of the Group or have other major appointments and professional qualifications. He does not have, and is not deemed to have any interests or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations which are required to be disclosed pursuant to Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). He does not have any relationship with other Directors, senior management, substantial or controlling Shareholders as defined in the GEM Listing Rules.

Save as disclosed above, Prof. Shen Zuojun has met the independent criteria set out in Rule 5.09 of the GEM Listing Rules and there are no other matters relating to the appointment of him that need to be brought to the attention of the Shareholders and there is no other information that should be disclosed pursuant to Rule 17.50(2)(h) to 17.50(2)(v) of the GEM Listing Rules.

The following are the particulars of the Supervisors proposed to be appointed and re-appointed at the AGM:

Dr. SHEN Sheng (沈勝博士) (“**Dr. Shen**”), aged 38, was appointed as a Supervisor on 8 January 2019. He is currently a comprehensive affairs and business executive and business supervisor of the Science and Technology Cooperation and Achievement Transformation Division* in IBP. He obtained a doctorate degree in cell biology from the University of Chinese Academy of Sciences in July 2013. Thereafter, he worked as an assistant research associate at the Key Laboratory of Infection and Immunity* (感染與免疫院重實驗室) of the Chinese Academy of Sciences. He joined the Company in January 2019.

The Company proposes to re-appoint Dr. Shen as a Supervisor to hold office for a term of three years until the expiration of the current session of the supervisory committee. Subject to the Shareholders’ approval at the AGM, his emoluments will be determined by the Board with reference to his responsibilities and performance of duties to the Company.

As at the Latest Practicable Date, Dr. Shen did not hold any directorship in other publicly listed company in Hong Kong or overseas in the last three years nor any other position with the Company or other members of the Group. In addition, he does not have any relationship with the other Directors, Supervisors, senior management or substantial or controlling Shareholders, nor has any interests in the Shares within the meaning of Part XV of the SFO. There is no other information which is discloseable, nor is/was he involved in any of the matters required to be disclosed pursuant to Rule 17.50(2)(h) to 17.50(2)(v) of the GEM Listing Rules. There is no other matter in relation to the proposed appointment of Dr. Shen as a Supervisor that needs to be brought to the attention of the Shareholders.

Mr. LI Jifeng (李繼峰先生), aged 44, is proposed to be appointed as a Supervisor. He served at the 69243 Army Hospital from 1994 to 2006. From 1999 to August 2006, he successively studied in the Laboratory Department, Ultrasound Department, and Physiotherapy Department of the General Hospital of the Military Region. From December 2006 to April 2016, he successively worked at Xinjiang Haokang Co., Ltd.* (新疆昊康公司), Sichuan Mike Co., Ltd.* (四川邁克公司), Japan Sysmex Co., Ltd.* (日本希森美康公司), Shanghai Pinluo Investment Co., Ltd.* (上海品羅投資有限公司) where he served as an application engineer, sales manager, regional director, and IVD investment consultant respectively. Furthermore, Mr. Li founded Xinjiang Senyu Huikang Co., Ltd.* (新疆森宇惠康公司) In November 2016, and Xinjiang Guoke Kangyi Co., Ltd.* (新疆國科康儀公司) in December 2017. He possesses 10 years of working experience at hospitals and 16 years in the medical industry. He obtained his bachelor's degree in medical testing (supervising examiner) (醫學檢驗(主管檢驗師)) from Shihezi University (石河子大學) in 2014.

Mr. Li Jifeng will enter into a service agreement with the Company upon his appointment as a Supervisor is approved by the Shareholders at the AGM. His term of service with the Company will take effect from the date of approval by the Shareholders at the AGM until the expiration of the term of the current session of the supervisory committee. His remuneration will be determined by the Board and the Remuneration Committee with reference to his duties and responsibilities, the performance of the Group and the prevailing market conditions.

As at the Latest Practicable Date, Mr. Li did not hold any directorship in other publicly listed company in Hong Kong or overseas in the last three years nor any other position with the Company or other members of the Group. In addition, he does not have any relationship with the other Directors, Supervisors, senior management or substantial or controlling Shareholders, nor has any interests in the Shares within the meaning of Part XV of the SFO. There is no other information which is discloseable, nor is/was he involved in any of the matters required to be disclosed pursuant to Rule 17.50(2)(h) to 17.50(2)(v) of the GEM Listing Rules. There is no other matter in relation to the proposed appointment of Mr. Li as a Supervisor that needs to be brought to the attention of the Shareholders.

SUPPLEMENTAL NOTICE OF THE ANNUAL GENERAL MEETING



中生北控生物科技股份有限公司
BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION
(a joint stock limited company incorporated in the People's Republic of China with limited liability)
(Stock Code: 8247)

SUPPLEMENTAL NOTICE OF THE ANNUAL GENERAL MEETING

Reference is made to the notice (the “**Original Notice**”) of the annual general meeting (the “**Meeting**”) of Biosino Bio-Technology and Science Incorporation (the “**Company**”) dated 6 April 2023, which sets out the resolutions to be considered and, if thought fit, to be approved at the Meeting to be held at No. 27 Chaoqian Road, Science and Technology Industrial Park, Changping District, Beijing, the People’s Republic of China (the “**PRC**”) on Thursday, 25 May 2023 at 10:00 a.m.

SUPPLEMENTAL NOTICE IS HEREBY GIVEN that the Meeting will be held as originally scheduled at the same time and venue. In addition to the resolutions contained in the Original Notice, the following new resolutions will also be considered and approved, if thought fit, at the Meeting. This supplemental notice should be read in conjunction with the Original Notice:

AS ORDINARY RESOLUTIONS

- 5A. To consider and approve the appointment and re-appointments of the following persons as directors of the Company (the “**Director(s)**”), and authorise the board (the “**Board**”) of Directors to fix their remuneration and to enter into service contracts with them subject to such terms and conditions as the Board shall think fit and to do all such acts and things to give effect to such matters:–
- (a) the re-appointment of Mr. Wu Lebin as an executive Director;
 - (b) the re-appointment of Dr. Sun Zhe as a non-executive Director;
 - (c) the re-appointment of Mr. Lu Qi as an independent non-executive Director;
 - (d) the re-appointment of Prof. Shen Jianguang as an independent non-executive Director;

SUPPLEMENTAL NOTICE OF THE ANNUAL GENERAL MEETING

- (e) the appointment of Mr. Chen Peng as an executive Director;
 - (f) the appointment of Mr. Chen Zhengyong as a non-executive Director;
 - (g) the appointment of Mr. Li Zhonghua as a non-executive Director;
 - (h) the appointment of Dr. Gao Guangxia as a non-executive Director; and
 - (i) the appointment of Prof. Shen Zuojun as an independent non-executive Director.
- 5B. To consider and approve the appointment and re-appointment of the following persons as supervisors of the Company and authorise the Board to fix their remuneration and to enter into service contracts with them subject to such terms and conditions as the Board shall think fit and to do all such acts and things to give effect to such matters:
- (a) the re-appointment of Dr. Shen Sheng as a supervisor of the Company; and
 - (b) the appointment of Mr. Li Jifeng as a supervisor of the Company.

For and on behalf of the Board
Biosino Bio-Technology and Science Incorporation
Tung Woon Cheung, Eric
Company Secretary

Beijing, the PRC, 10 May 2023

SUPPLEMENTAL NOTICE OF THE ANNUAL GENERAL MEETING

Notes:

- i. A member of the Company (“**Member**”) entitled to attend and vote at the Meeting is entitled to appoint a proxy or proxies to attend and vote in his stead. A proxy needs not be a Member. A revised form of proxy (the “**Revised Proxy Form**”) for use at the Meeting is enclosed herewith. In the case of the joint holders of any Share, only the person whose name appears first in the register of members shall be entitled to receive this notice, to attend and exercise all the voting powers attached to such share at the Meeting, and this notice shall be deemed to be given to all joint holders of such share.
- ii. To be valid, the Revised Proxy Form together with any power of attorney or other authority (if any) under which it is signed or a notarially certified copy of that power of attorney or authority must be deposited with the Company’s H share registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, and in case of holders of domestic shares, to the Company’s mailing address at No. 27 Chaoqian Road, Science and Technology Industrial Park, Changping District, Beijing, the PRC, postal code 102200, not later than 24 hours before the time appointed for holding the Meeting or the time appointed for passing the resolutions or any adjournment thereof. Delivery of the Revised Proxy Form shall not preclude a Member from attending and voting in person at the Meeting and, in such event, the instrument appointing a proxy shall be deemed to be revoked.
- iii. Members and their proxies should produce identity proof (and form of proxy in case of proxies) when attending the Meeting.
- iv. It is expected that the Meeting will last not more than half a day. Members and their proxies attending the Meeting shall bear their own travel and accommodation expenses.
- v. If you wish to appoint a proxy to attend and vote at the Meeting on your behalf and if you have not yet returned the proxy form (the “**First Proxy Form**”) dated 6 April 2023, you should complete, sign and return the accompanying Revised Proxy Form to Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong no later than 48 hours before the time appointed for holding the Meeting or any of its adjournments (as the case may be) (the “**Closing Time**”). In this case, the First Proxy Form should not be submitted.
- vi. If you wish to appoint a proxy to attend and vote at the Meeting on your behalf, and have already duly completed and submitted the First Proxy Form to the Company, you should note that:
 - (a) if no Revised Proxy Form is submitted to the Company, the First Proxy Form correctly completed and duly lodged will be treated as a valid proxy form submitted by you. The proxy so appointed shall be required to vote in such manner as he/she may be directed under the First Proxy Form and, in respect of the resolutions set out in this supplemental notice, the proxy will be entitled to vote at his/her discretion or to abstain from voting on such resolutions;
 - (b) if the Revised Proxy Form is duly completed and submitted by the Closing Time, such Revised Proxy Form will revoke and supersede the First Proxy Form submitted by you. Such Revised Proxy Form will be treated as a valid proxy form submitted by you; and
 - (c) if the Revised Proxy Form is submitted after the Closing Time, such Revised Proxy Form will be invalid and the validity of the First Proxy Form correctly completed and duly submitted by you will not be affected. The proxy appointed by you under the First Proxy Form (if duly completed) will be entitled to vote in the manner as mentioned in (a), as if the Revised Proxy Form is not lodged.